Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 17;14(1):11323.
doi: 10.1038/s41598-024-61808-7.

Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor

Affiliations

Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor

Frederic Brösecke et al. Sci Rep. .

Abstract

Oxalate, a uremic toxin that accumulates in dialysis patients, is associated with cardiovascular disease. As oxalate crystals can activate immune cells, we tested the hypothesis that plasma oxalate would be associated with cytokine concentrations and cardiovascular outcomes in dialysis patients. In a cohort of 104 US patients with kidney failure requiring dialysis (cohort 1), we measured 21 inflammatory markers. As IL-16 was the only cytokine to correlate with oxalate, we focused further investigations on IL-16. We searched for associations between concentrations of IL-16 and mortality and cardiovascular events in the 4D cohort (1255 patients, cohort 2) and assessed further associations of IL-16 with other uremic toxins in this cohort. IL-16 levels were positively correlated with pOx concentrations (ρ = 0.39 in cohort 1, r = 0.35 in cohort 2) and were elevated in dialysis patients when compared to healthy individuals. No significant association could be found between IL-16 levels and cardiovascular events or mortality in the 4D cohort. We conclude that the cytokine IL-16 correlates with plasma oxalate concentrations and is substantially increased in patients with kidney failure on dialysis. However, no association could be detected between IL-16 concentrations and cardiovascular disease in the 4D cohort.

Keywords: Cardiovascular events; Chronic kidney disease; Cytokines oxalate; Dialysis; Interleukin-16.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Interleukin-16 correlates with plasma oxalate concentrations in patients with kidney failure requiring long-term dialysis (cohort 1). In 104 patients with kidney failure requiring long-term dialysis in the US (cohort 1), plasma oxalate (pOx) concentration, measured by enzymatic assay, and 21 cytokines, measured by a V-PLEX Proinflammatory Panel 1 Human, a V-PLEX Cytokine Panel 1 Human, and an Interleukin(IL)-33-ELISA, were assessed. (A) IL-16 was the only cytokine that correlated with pOx. Scatter plot with regression line (black line). Spearman`s rank test, ρ = 0.39, p < 0.001. (B) The levels of the remaining 20 cytokines did not significantly correlate with pOx concentration. Scatter plots with regression lines and results of the Spearman correlation analysis (Spearman`s rank test; ρ and p-value).

References

    1. Himmelfarb J, Vanholder R, Mehrotra R, Tonelli M. The current and future landscape of dialysis. Nat. Rev. Nephrol. 2020;16:573–585. doi: 10.1038/s41581-020-0315-4. - DOI - PMC - PubMed
    1. Johansen KL, et al. US renal data system 2021 annual data report: Epidemiology of kidney disease in the United States. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2022;79:A8–A12. doi: 10.1053/j.ajkd.2022.02.001. - DOI - PMC - PubMed
    1. Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis. Nephrol. Dial Transplant. 2018;33:35–40. doi: 10.1093/ndt/gfy175. - DOI - PMC - PubMed
    1. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658. doi: 10.1046/j.1523-1755.1999.00273.x. - DOI - PubMed
    1. Duranton F, et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. 2012;23:1258–1270. doi: 10.1681/ASN.2011121175. - DOI - PMC - PubMed